This is a comprehensive review focusing on the utilization of slaughter blood proteins as sources of bioactive peptides for functional food applications. Despite significant advances in bioactive peptide research, critical knowledge gaps remain regarding species-specific variations in peptide bioactivity and the complex interplay between processing methods and functional properties. Enzymatic hydrolysis using various proteases generates peptides with diverse bioactivities, including antioxidant, anti-inflammatory, ACE-inhibitory, and DPP-IV inhibitory effects. This review uniquely integrates proteolytic mechanisms with in-depth molecular characterization across multiple animal sources, addressing the previously fragmented understanding of structure-function relationships. Notably, gastrointestinal stability is significantly enhanced by proline residues and hydrophobic amino acids, offering a novel structural insight for predicting peptide bioavailability. Hemoglobin decolorization methods enable broader food industry applications. Recent innovations in processing technologies and delivery systems position blood-derived peptides as valuable functional ingredients for sustainable food systems.
Goat blood, a major slaughterhouse by-product, was systematically valorized into dual-function bioactive peptides through an optimized four-step process. Four blood preparations—whole blood (HB), anticoagulant-treated blood (HBS), red blood corpuscles (BC), and plasma (PM)—were subjected to heat pretreatment (90 °C, 15 min) and enzymatic hydrolysis. Neutrase hydrolysis of heat-pretreated whole blood at 8% substrate concentration for 4 h (HBN-8) yielded optimal protein recovery (44.38%) with dual ACE (88.24%) and DPP-IV (81.13%) inhibition. Ultrafiltration enriched bioactive peptides in the ≤3 kDa fraction (DPP-IV: 87.8%; ACE: 65.5%). LC-MS/MS de novo sequencing identified 14 novel peptide sequences (4–9 amino acids), with the most potent SEC fraction showing IC50 values of 0.89 and 0.45 mg Leu eq./mL for DPP-IV and ACE inhibition, respectively. Critically, simulated gastrointestinal digestion enhanced rather than diminished bioactivity, with ACE inhibition increasing progressively to 60.91% at the intestinal phase, supported by predicted generation of bioactive fragments from parent sequences. Caco-2 assays confirmed peptide safety (100–1000 µg/mL) and demonstrated 10.47% transepithelial transport with retained dual inhibitory activities. This study establishes goat blood as a sustainable source of orally bioavailable, GI-stable peptides for the development of functional foods targeting hypertension and type 2 diabetes.